A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.

Trial Profile

A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms POTENT
  • Most Recent Events

    • 10 Nov 2012 Interim results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 10 Nov 2012 Primary endpoint 'Seroconversion-rate' has not been met.
    • 25 Aug 2011 New source identified and integrated (Korean Clinical Trials Register KCT0000042).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top